Of more than 400 phase 3 cancer trials evaluated, 32% had complete toxicity reporting, and 46% included toxicity-minimizing language. In phase 3 cancer trials, toxicity data are “often incompletely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback